Welcome to our dedicated page for Ovintiv SEC filings (Ticker: OVV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Proved reserves tables, derivative hedging footnotes, and multi-basin production data make an Ovintiv Inc. (OVV) 10-K feel like a technical manual. If you have ever searched for “Ovintiv SEC filings explained simply” or wondered how to spot executive stock sales before the market reacts, you know the challenge. Stock Titan solves it by turning dense disclosures into insights you can use immediately.
Our AI reads every submission the moment it reaches EDGAR and delivers plain-English summaries, peer benchmarks and red-flag alerts. Whether you need the “Ovintiv quarterly earnings report 10-Q filing” to track drilling efficiency, the “Ovintiv 8-K material events explained” after a new well test, or “Ovintiv proxy statement executive compensation” details, you’ll find it here—complete, searchable and updated in real time. We also surface “Ovintiv insider trading Form 4 transactions” and give you “Ovintiv Form 4 insider transactions real-time” notifications so you can monitor management’s moves without scanning PDFs.
Curious what matters inside each form? Our platform maps disclosures to investor questions:
- 10-K / annual report – reserve volumes, capital spending, risk factors; see it as the “Ovintiv annual report 10-K simplified.”
- 10-Q / quarterly earnings – production shifts and hedge gains; get automatic “Ovintiv earnings report filing analysis.”
- 8-K – material guidance changes, asset sales, or environmental incidents.
- Form 4 – “Ovintiv executive stock transactions Form 4” with trend charts.
On 07/01/2025, Jason Phipps, SVP Global Sales and Marketing of Ciena Corporation (CIEN), filed a Form 4 reporting the sale of 2,325 common shares at $80.50 each, a transaction worth roughly $187 k. The trade was executed under a pre-arranged Rule 10b5-1 plan dated 10/09/2024.
After the sale, Phipps directly owns 84,833 CIEN shares, including unvested RSUs and PSUs. The disposal equals about 2.7 % of his reported holdings, leaving a substantial ownership stake that continues to align management and shareholder interests.
No derivative transactions were disclosed. Given the small size relative to his remaining position and the 10b5-1 framework, the event appears routine with limited market impact for CIEN investors.
Freshworks Inc. (FRSH) filed a Form 4 disclosing that non-employee director Randy Gottfried received an annual equity grant of 13,236 Class A RSUs on 01-Jul-2025. The award, made under the company’s Non-Employee Director Compensation Policy, carries an exercise/price of $0 and converts 1-for-1 into common shares. The RSUs vest in full on 01-Jul-2026, or earlier should the director fail to be re-elected at the next annual meeting. After the grant Mr. Gottfried’s direct beneficial ownership rises to 53,920 shares. No derivative security transactions were reported. The filing is routine, reflects standard board compensation and results in de-minimis dilution relative to FRSH’s ~300 million shares outstanding.
Alight, Inc. (ALIT) – Form 4 insider transaction
Director William P. Foley II received 3,147 Class A common shares on 30 June 2025 as his quarterly board retainer, electing stock in lieu of a $17,813 cash payment. The grant price was the closing price of $5.66.
After the award, Foley holds 902,165 shares directly and 6,833,304 shares indirectly through Trasimene Capital FT, LLC and Bilcar FT, LP, for a combined beneficial position of roughly 7.7 million shares. No derivative securities were reported, and no dispositions occurred.
The filing does not indicate any change in board roles or corporate strategy; it simply updates Foley’s ownership under Alight’s 2021 Omnibus Incentive Plan.
ArriVent BioPharma, Inc. (Nasdaq: AVBP) has launched a follow-on public offering consisting of 2,482,692 shares of common stock and pre-funded warrants for up to 1,363,469 additional shares. The securities are priced at $19.50 per share (warrant price $19.4999; exercise price $0.0001).
The base deal will generate $75.0 million in gross proceeds. After underwriting fees of 6 % ($1.17 per share) and estimated expenses, net proceeds are expected to be $69.8 million. Underwriters hold a 30-day option for 576,923 extra shares that would lift gross proceeds to $86.3 million and net proceeds to roughly $80.4 million. The financing increases shares outstanding to 36.5 million (37.1 million if the option is exercised) before any warrant conversion.
Use of proceeds: funds will support clinical development of lead EGFR inhibitor firmonertinib, advance other oncology pipeline programs, and provide general working capital.
Clinical backdrop: Firmonertinib holds FDA Breakthrough Therapy and Orphan Drug designations. Interim data show 79 % ORR in EGFR exon-20 NSCLC (FAVOUR) and 68 % ORR at a 240 mg dose in PACC mutations (FURTHER), with favourable CNS activity and no Grade 4/5 TRAEs. A global Phase 3 PACC study (ALPACCA – FURMO-006) is scheduled to begin 2H 2025.
Capital structure impacts: investors will see an immediate book-value dilution of $12.32 per share. Additional dilution is possible from 4.1 million outstanding stock options (WAEP $14.96), 3.8 million shares reserved for future awards, 3.4 million shares already sold under an at-the-market facility, and any exercise of the new pre-funded warrants. ArriVent also owes up to $765 million in milestones to its partner Shanghai Allist for global rights to firmonertinib.
Key terms of the pre-funded warrants: no expiration, exercisable any time for $0.0001 per share, subject to 4.99 %/9.99 % beneficial-ownership caps, and will not be listed for trading.
Timeline: closing and delivery are expected on or about 3 July 2025.
Borr Drilling Limited (BORR) has launched a preliminarily marketed public offering of 50 million common shares via a two-step settlement structure. Approximately 30 million shares are expected to settle on 7 July 2025 (the “First Settlement”) while the remaining 20 million will settle on or about 7 August 2025 (the “Second Settlement”) only if shareholders approve an increase in authorised share capital at a Special General Meeting (SGM) on 6 August 2025. The shares are listed on the NYSE; the last reported price on 1 July 2025 was $1.95.
Net proceeds—whose exact amount will depend on final pricing—are earmarked for general corporate purposes such as debt service, capital expenditure and working-capital needs. The equity raise is also a condition precedent for agreed amendments to Borr’s financing package: commitments have been received to lift the Super Senior Revolving Credit Facility to $200 million (+$50 million), re-classify the $45 million guarantee line, and add a new $34 million senior secured RCF, jointly raising available liquidity by more than $100 million and easing covenant thresholds (lower liquidity minimum, higher leverage ceiling, lower coverage ratios).
Operationally, Borr has booked 13 new contract awards/LOIs/LOAs in 2025, adding ~3,010 potential rig-days and $366 million of revenue backlog (average day-rate $121k). Contract coverage now stands at 84% for 2025 and 45% for 2026 at average day-rates of $144k and $141k, respectively.
Leadership refresh: CCO Bruno Morand will become CEO on 1 September 2025; current CEO Patrick Schorn will transition to Executive Chair, while Chairman Tor Olav Trøim will remain on the board. Investor Granular Capital’s CIO, Thiago Mordehachvili, is nominated to join the board, contingent on SGM approval to expand board size.
Several insiders—Schorn ($1 m), Morand ($0.3 m) and Drew Holding Ltd. ($10 m)—intend to subscribe, all electing to receive shares in the Second Settlement. If the SGM fails, only the First Settlement closes, leaving the remaining 20 million shares undelivered.
Centene Corporation (CNC) Form 4 filing: Director Frederick H. Eppinger reported the acquisition of 463 shares of common stock on 06/30/2025 at a stated price of $0.00, indicating an equity award rather than an open-market purchase. Following the transaction, Eppinger directly owns 359,042.658 shares, which includes 5,965 restricted stock units (RSUs) subject to future vesting. No derivative securities transactions were reported. The filing was signed by attorney-in-fact Christopher A. Koster on 07/02/2025.
The transaction modestly increases the director’s stake by approximately 0.13%, providing incremental alignment with shareholder interests but does not represent a market-based purchase. No other insider transactions or material events were disclosed in this short-form filing.
Form 4 filing for KORU Medical Systems, Inc. (KRMD) discloses that director Shahriar Matin acquired 4,189 shares of common stock on 07/02/2025 at a reported price of $3.58 per share. Following the transaction, Matin’s direct ownership increased to 87,604 shares. No derivative security activity or additional explanatory notes beyond the standard boiler-plate language were provided. The filing was signed by Attorney-in-Fact Thomas Adams.
On June 30 2025, Ovintiv Inc. (OVV) director Ralph Izzo received 40 Deferred Share Units (DSUs) as a dividend equivalent, recorded in a Form 4 filing. Each DSU economically equals one common share and will be held until the director retires from the Board. The transaction was priced at $0, reflecting a non-cash, routine accrual of board compensation. Following the allocation, Izzo’s total direct ownership increases to 5,125 DSUs. No derivative exercises, open-market purchases, or sales occurred, and there is no indication of any change in corporate strategy or insider sentiment beyond ordinary board compensation.
Stratus Properties Inc. (STRS) – Form 4 filing: Director Laurie L. Dotter acquired 321 shares of STRS common stock on 07/01/2025 at an average price of $18.88 per share. The shares were issued pursuant to her prior election to receive a portion of her annual board retainer in equity rather than cash, rather than an open-market purchase. Following the transaction, Dotter’s total beneficial ownership increased to 18,273 shares, which includes 3,730 restricted stock units (RSUs). The filing shows the transaction was executed directly and no derivative securities were involved.
The disclosed purchase is modest in absolute terms and represents routine director compensation, but it modestly aligns the director’s economic interests with shareholders by converting cash fees into equity. There is no indication of simultaneous sales or other insider transactions.
FAQ
What is the current stock price of Ovintiv (OVV)?
What is the market cap of Ovintiv (OVV)?
What is Ovintiv Inc.'s primary business?
How is Ovintiv organized in terms of operations?
What distinguishes Ovintiv in the upstream energy sector?
Which markets does Ovintiv serve?
How does Ovintiv manage its operational risks?
What are some industry-specific strategies used by Ovintiv?
How does Ovintiv reinforce its market position?
